非维生素K口服抗凝药在瓣膜性心房颤动中的应用研究进展  

Research Progress of Application of Non-vitamin K Oralanticoagulants in Valvular Atrial Fibrillation

作　　者：张晓晴 李树仁[2] 牛绍乾 唐子健 李文静[1] 郝潇[2] 陈佳仑 吕晓 ZHANG Xiaoqing;LI Shuren;NIU Shaoqian;TANG Zijian;LI Wenjing;HAO Xiao;CHEN Jialun;LYU Xiao(Graduate School of Hebei Medical University,Shijiazhuang 050017,China;Department of Cardiology,Hebei General Hospital,Shijiazhuang 050000,China;College of Graduate School,North China University of Science and Technology,Tangshan 063210,China)

机构地区：[1]河北医科大学研究生院,河北省石家庄市050017 [2]河北省人民医院心内科,河北省石家庄市050000 [3]华北理工大学研究生院,河北省唐山市063210

出　　处：《实用心脑肺血管病杂志》2020年第7期11-15,共5页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：瓣膜性心房颤动(AF)的定义一直以来饱受争议,非维生素K口服抗凝药(NOACs)在瓣膜性AF患者中应用的证据尚不足。本文就瓣膜性AF定义的演变及目前NOACs治疗瓣膜性AF患者的有效性及安全性证据进行综述,指出NOACs在中重度风湿性左房室瓣狭窄、机械性人工心脏瓣膜置换术后的AF患者中应用证据尚不足,而其在除此以外的瓣膜病性AF患者中的应用有一定疗效与安全性优势,但仍需大型随机对照试验进一步验证。The definition of valvular atrial fibrillation(AF)has long been controversial,and the evidence for the application of non-vitamin K oralanticoagulants(NOACs)in patients with valvular AF is still insufficient.This paper reviewed the evolution of the definition of valvular AF and the evidence for the efficacy and safety of NOACs in patients with valvular AF,and pointed out that there were insufficient evidences for the application of NOACs in AF patients with moderate to severe rheumatic mitral stenosis and mechanical heart valves,and its application in patients with other valvular AF had certain efficacy and safety advantages.However,it still needs to be verified in large-scale RCT.

关 键 词：心房颤动 瓣膜性心房颤动 非维生素K口服抗凝药 综述 

分 类 号：R541.75[医药卫生—心血管疾病]